Bicycle Therapeutics was founded in 2009 based on innovative science conducted in the laboratory of the globally respected Professor Sir Greg Winter, a pioneer in monoclonal antibodies, to translate first-in-class Bicycles into transformative medicines for life-altering diseases.
The venture has become a transatlantic company, with headquarters in Cambridge UK and many key functions and members of the leadership team located in the biotech hub of Boston, Mass.
Its proprietary bicyclic peptide (Bicycle®) product platform has captured attention from Big Pharma and cancer practitioners alike.
In May 2018, Bicycle Therapeutics expanded its collaboration with AstraZeneca to include additional targets in respiratory and cardio-metabolic diseases.
The original collaboration was signed in late 2016 and with the expansion has a potential value in excess of $1 billion. Under the terms of the collaboration Bicycle is responsible for identifying Bicycles® for an undisclosed number of respiratory, cardiovascular and metabolic disease targets specified by AstraZeneca, while AstraZeneca is responsible for further development and product commercialisation.
In May 2019, Bicycle confirmed to Business Weekly that the company was targeting an $86 million IPO on the US technology market Nasdaq.